Wegner Rodney E, Beriwal Sushil, Heron Dwight E, Richard Scott D, Kelly Joseph L, Edwards Robert P, Sukumvanich Paniti, Zorn Kristin K, Krivak Thomas C
Department of Radiation Oncology, Magee-Womens Hospital of UPMC, Pittsburgh, PA 15213, USA.
Brachytherapy. 2010 Jul-Sep;9(3):260-5. doi: 10.1016/j.brachy.2009.08.013. Epub 2010 Feb 1.
With the increasing elderly population, more women with newly diagnosed endometrial cancer may not be surgical candidates due to medical comorbidities. Definitive radiation therapy with external beam radiation (EBRT) and/or brachytherapy is a reasonable primary treatment for endometrial cancer in patients who cannot undergo surgery.
A retrospective review identified 26 women 75 years and older with endometrial cancer who were not operative candidates due to comorbidities and received definitive radiation.
The median age of the treated patients was 83, all of whom had significant medical comorbidities precluding surgical treatment. Seventy-three percent of the patients had stage T1 disease, 19% were stage T2, and 8% were stage T3. Seventy-three percent of patients received EBRT before brachytherapy (median dose: 45 Gy). The median brachytherapy dose was 20 Gy in 5 fractions. The types of brachytherapy used were Rotte Y applicator (42%), tandem and cylinder (42%), and ring and tandem (16%). Median followup was 12 months (1-60 months). No treatment breaks were required for the entire group and only 2 patients (8%) developed late toxicity. The overall survival for all patients was 89% and 28% at 1 and 2 years, respectively. Disease-specific survival for all patients was 93% at 1 year and 73% at 3 years.
The results in this study indicate that definitive radiation with EBRT and/or brachytherapy for endometrial cancer is feasible and well tolerated in an elderly population.
随着老年人口的增加,更多新诊断出子宫内膜癌的女性可能因合并症而不适合手术。对于无法接受手术的子宫内膜癌患者,外照射放疗(EBRT)和/或近距离放疗的确定性放疗是一种合理的主要治疗方法。
一项回顾性研究确定了26名75岁及以上的子宫内膜癌女性患者,她们因合并症而不适合手术,并接受了确定性放疗。
接受治疗患者的中位年龄为83岁,所有患者均有严重合并症,无法进行手术治疗。73%的患者为T1期疾病,19%为T2期,8%为T3期。73% 的患者在近距离放疗前接受了EBRT(中位剂量:45 Gy)。近距离放疗的中位剂量为20 Gy,分5次进行。使用的近距离放疗类型为Rotte Y施源器(42%)、串形施源器和柱状施源器(42%)以及环形施源器和串形施源器(16%)。中位随访时间为12个月(1 - 60个月)。整个组无需中断治疗,只有2名患者(8%)出现晚期毒性反应。所有患者1年和2年的总生存率分别为89%和28%。所有患者1年和3年疾病特异性生存率分别为93%和73%。
本研究结果表明子宫内膜癌采用EBRT和/或近距离放疗的确定性放疗在老年人群中是可行且耐受性良好的。